Affinivax Inc., a Cambridge, Mass.-based startup developing a pneumococcal vaccine, closed a $226 million Series C round co-led by new investors Rock Springs Capital and Foresite Capital. Additional new investors T. Rowe Price, Wellington Management, funds and accounts managed by Blackrock, Cormorant Asset Management, Perceptive Advisors, EcoR1 Capital, Surveyor Capital and Logos Capital also participated in the funding, and were joined by returning backers Viking Global Investors, Bain Capital Life Sciences and Ziff Capital Healthcare Ventures. Kris Jenner, founder and partner at Rock Springs Capital, joined the company’s board.
Resident, a mattress and home goods platform, snagged a $130 million Series B investment. Crossover Partners and Nexus Capital Management led the round, which included participation from Baron Capital Group.
DiCE Molecules, a South San Francisco, Calif.-based biopharmaceutical startup, completed an $80 million Series C round led by RA Capital Management. New investors Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Osage University Partners and Asymmetry Capital Management also participated in the funding, along with existing backers Northpond Ventures, Sands Capital, Sanofi Ventures, Alexandria Venture Investments, Altitude Life Science Ventures and Agent Capital. Jake Simson, partner at RA Capital, will join the board.
Glia, a New York- and Estonia-based digital customer service provider, raised $78 million in Series C funding led by Insight Partners.
Endeavor BioMedicines, a Solana Beach, Calif.-based startup whose idiopathic pulmonary fibrosis treatment candidate will enter Phase II trials later this year, landed $62 million in Series A financing led by Omega Funds, Longitude Capital and Endeavor’s management.
Kira Pharmaceuticals, a Cambridge, Mass.- and China-based developer of therapies to treat immune-mediated diseases, picked up a $53.5 million Series B+ investment. RA Capital Management and Vivo Capital co-led the round, which included support from Foresite Capital, APlus Partners, Quan Capital and Qiming Venture Partners USA.
LifeMine Therapeutics Inc., a Cambridge, Mass.-based startup that uses a genomics-based platform to identify new medicines from fungi, raised $50 million in Series B funding. Rick Klausner and Milky Way Investments led the round, with participation from GV, WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital and MRL Ventures Fund. William G. Kaelin Jr. was appointed to the company’s board.
Oxbotica, a U.K.-based autonomous vehicle software developer, nabbed $47 million in Series B financing from BGF, bp Ventures, Halma, HostPlus, IP Group,Tencent, Venture Science and funds advised by Doxa Partners.
Abcuro Inc., a Newton, Mass.-based startup developing immunotherapies for autoimmune diseases and cancer, snagged $42 million in Series A1 funding. Mass General Brigham Ventures and Sanofi Ventures co-led the round, which included support from Pontifax Venture Capital, Hongsen Investment Group, RA Capital Management and Samsara BioCapital. In addition to the financing, David de Graaf was appointed chief executive. He was most recently CEO of Comet Therapeutics. Sanofi Ventures’ Jason Hafler, Pontifax’s Iyona Rajkomar, RA Capital’s Ryan Berry and Samsara BioCapital’s Donald McCarthy have joined Abcuro’s board.
Carrum Health Inc., a South San Francisco, Calif.-based digital health-care marketplace, scored a $40 million Series A round. Tiger Global Management led the investment, which saw support from GreatPoint Ventures, Cross Creek, Wildcat Venture Partners and SpringRock Ventures.
Outstanding Foods, a Los Angeles plant-based snack brand, collected $10 million in Series A financing led by SternAegis Ventures.
|